☆ 4.4 Editorial Material

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

DIABETES THERAPY (2022)

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations and tools to evaluate quality of care. It is updated regularly by a committee of experts.

DIABETES CARE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Martin R. Cowie et al.

NATURE REVIEWS CARDIOLOGY (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Andre J. Scheen

NATURE REVIEWS ENDOCRINOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Review Medicine, General & Internal

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker et al.

LANCET (2019)

添加到收藏夹

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D

相关参考文献

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

导出引文

分享论文